INVA · NASDAQ
Healthcare · Biotechnology
$21.31
+0.90%
Close on Oct 29, 2026
Research data through 2026-10-29
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Free research · no account required
Research data through Oct 29, 2026. Research is updated periodically, not in real time.
56
of 100 · stored research reading
Stored Quality research reads 56 of 100, a middle-of-the-universe reading. The measurements behind it are mixed.
Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.
How this is measured68
of 100 · stored research reading
Stored Fundamental Momentum research reads 68 of 100. Stored measurements classify recent reported fundamentals as accelerating. This describes reported financial change already disclosed, with no forward-looking claim.
Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.
How this is measured94
of 100 · stored research reading
Stored Capital Returns research reads 94 of 100, recorded as exceptional. No dividend is recorded for this company, so the reading rests on buybacks and dilution control. Share count has been reduced at about 6.1% a year in the stored window.
Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.
How this is measuredStored ratios recorded at the last research date (2026-10-26). Valuation Intelligence remains research context and is not a validated allocation signal.
Learn the basics of valuationInvestor intelligence
The research below is part of Investor membership. Values are withheld from this page entirely — nothing premium is loaded into it. Start the free trial and the intelligence you asked for unlocks right here.
Investor
Unlock its Pro Investor Score and ranking across the research universe.
7 days · No credit card required
Investor
Unlock Risk Intelligence, Price Risk, and Market Confirmation.
7 days · No credit card required
Investor
Unlock the Pro Research Brief with What Changed & Why, research history and tensions.
7 days · No credit card required
Investor
Unlock Pro Investor Intelligence: disclosed professional-manager and insider activity beside company research.
7 days · No credit card required
Investor
Unlock Pro Investor AI to ask questions grounded in Pro Investor Academy research and evidence.
7 days · No credit card required
Investor
Save companies and monitor how their research changes over time.
7 days · No credit card required
Explore other companies in this industry. These are objective industry neighbours, not suggested alternatives.
Pro Investor Academy continuously applies its research rules across the eligible universe and surfaces a small number of investments for deeper research when they qualify.
Appears in
Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.
Plain-English definitions, with the formula and the limitations of each measure.
In the company’s own words
Innoviva, Inc. ("Innoviva", the "Company", the "Registrant" or "we" and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic healthcare assets.
Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited ("GSK"), including RELVAR /BREO ELLIPTA (fluticasone furoate/vilanterol, "FF/VI") and ANORO ELLIPTA (umeclidinium bromide/vilanterol, "UMEC/VI"). Under the Long-Acting Beta-2 Agonist ("LABA") Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR /BREO ELLIPTA as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO ELLIPTA , which tier upward at a range from 6.5% to 10%.
Our wholly owned, robust critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:
GIAPREZA (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock;
Quoted from the business section of this company’s 10-K filed February 25, 2026. Read the filing
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.
